A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis
Glomerulonephritis Minimal Lesion

Interventions

DRUG: frexalimab
DRUG: brivekimig
DRUG: rilzabrutinib
DRUG: placebo

Sponsor

Sanofi